NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live ...

编者荐语： 这个月中规中矩 以下文章来源于AI产品榜 ，作者李榜主 AI产品榜 . AI产品榜 aicpb.com 按月发布AI产品榜单。AI产品榜大会，是你必参的会。 发起人：李榜主 wx：QBB2378 第 11 期 AI产品榜·应用榜(APP) （2025 年 06 月）由 AI产品榜、36kr、硅星人、 沃垠AI、小熊跑的快 联名发布。 AI产品榜 2025 年 06 月榜 本文里包含 9 个 AI 榜单，更多 AI产品榜单直接访问官网 AI产品榜 aicpb.com 。 | AI产品榜·应用榜（APP） | | | | --- | --- | --- | | 全球总榜 | MAU | 全球MAU增速榜 | | 国内总榜 | MAU | 国内MAU增速榜 | | 出海总榜 | MAU | 全球MAU降速榜 | | 全球下载榜 | | 国内下载榜 | | 订阅收入榜 | | | 引用数据标注来源：【公众号@ AI产品榜 aicpb.com 】 AI 发展到今天，我们想，要完全发挥 AI 的能力，不仅需要软件，还需要硬件，甚至需要一个新的计算终端设备。 所以，在AI产品榜发榜 2 周年之际：我们将举办 A ...

2025年，音乐行业正经历着一场前所未有的变革，而人工智能音乐人的崛起，就是其中一股最大的冲击潮。 从Aventhis到The Devil Inside，这些所谓的非真人AI音乐"艺术家"，正凭借AI的力量大规模涌入主流音乐流媒体平台，给传统音乐生态带来了巨大冲击， 敲响了行业危机的警钟。 本周，MBW对Aventhis的报道在音乐界掀起了轩然大波。大家都推测这不是真人艺术家，Aventhis的YouTube频道的匿名所有者也写道："声音和图像是在 人工智能的帮助下创建的。歌词是我写的。" 一股令人胆寒的趋势正在发生——人类创作者在音乐平台的"人气"竟然开始干不过机器音乐人了。 如今，每天有超过20000条完全由人工智能生成的轨迹充斥着Deezer的平台。4月份，机器人制作的音频占"上传内容总量"的18%。 02 这位乡村"艺术家"，由AI生成的曲目在Spotify上每月竟能吸引超100万听众，这一数据足以让众多传统音乐人瞠目结舌。 01 而Aventhis并非个例，另一支人工智能生成乐队The Devil Inside同样备受欢迎，在Spotify上每月也拥有近70万听众。 The Devil Inside ...

Core Viewpoint - The rise of AI singer Yuri, created by AI.TALK, marks a significant moment in the AI music industry, with her debut music video "SURREAL" achieving over 7 million views across platforms, indicating a growing acceptance and interest in AI-generated music [1][7]. Group 1: AI Singer Development - The success of Yuri is attributed to advancements in music and video generation models, allowing for high-quality production that blurs the line between AI and human-generated content [7][12]. - Unlike previous virtual idols, Yuri represents a new wave of AI singers that can create music autonomously, leveraging AI models for both music composition and video production [6][8]. Group 2: Market Dynamics - The AI digital human market in China is projected to reach approximately 4.12 billion yuan in 2024, with a year-on-year growth of 85.3%, highlighting the rapid expansion of this sector [12]. - The commercial potential of AI singers is compared to traditional virtual idols, suggesting that AI singers can replicate successful monetization strategies such as merchandise, concerts, and collaborations [8][11]. Group 3: Challenges and Opportunities - Despite the potential, AI singers face challenges in achieving widespread recognition and maintaining audience engagement, as seen with other AI singers like Qiyue, which struggled to gain traction despite significant backing [10][11]. - The ability to create high-quality music and videos is essential for the commercial success of AI singers, as the market becomes increasingly competitive with more entrants expected [12][13].

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact of Alzheimer’s disease in the United States and the importance of brain health during this year’s Alzheimer’s & Brain Awareness Month. “Alzheimer’s & Brain Awareness Month offers the perfect opportunity for all Ame ...

Axsome Therapeutics (AXSM) FY Conference Summary Company Overview - **Company**: Axsome Therapeutics - **Focus**: Development of innovative medicines for central nervous system (CNS) disorders, addressing significant unmet needs in psychiatry and neurology [2][3] Industry Context - **CNS Disorders**: Over 150 million people in the U.S. are affected by serious CNS conditions, which have been historically underserved by the biopharma industry [2][3] - **Key Conditions**: Major depressive disorder (MDD), Alzheimer's disease agitation, smoking cessation, ADHD, binge eating disorder, obstructive sleep apnea, migraine, narcolepsy, fibromyalgia, and shift work disorder [3][4] Core Strategies - **Five Pillars of Innovation**: 1. **Novel Mechanisms of Action**: Focus on distinct treatment outcomes in areas with multiple existing products [4] 2. **Multi-Mechanistic Modes of Treatment**: Examples include Ovelity and Cymbravo [5] 3. **Clinical Trial Innovation**: Designing trials to effectively detect signals from active molecules [5] 4. **Molecular Drug Delivery**: Innovative delivery methods for CNS-active molecules [6] 5. **Diversified Pipeline**: A singular neuroscience pipeline with three commercial products and multiple late-stage programs [6][7] Financial Highlights - **Potential Peak Sales**: Total potential peak sales across the pipeline estimated at $16.5 billion, with approved products like Avelity, Synoscience, and Bravo projected to reach $2 billion to $4.5 billion [8] - **Cash Position**: $300 million in cash resources as of the end of Q1, sufficient to reach cash flow positivity [39][40] Product Updates - **Ovelity**: Rapid growth with an annualized run rate of $400 million; over 50% of prescriptions are first-line treatments [11][14] - **Sunosi**: Steady growth with an annualized run rate of $100 million, focusing on potential label expansion [17] - **Simbravo**: Newly approved for acute migraine treatment, launching imminently [12][18] Clinical Trials and Regulatory Updates - **Cymbravo**: Approved earlier in the year, with positive Phase III clinical trial readouts [9] - **AXS-five**: NDA submission for Alzheimer's disease agitation on track for Q3; high unmet need with 7 million adults affected [21][22] - **Salriamfetol**: Exploring additional indications including ADHD and major depressive disorder, with ongoing trials [25][28] - **AXS-twelve**: NDA submission planned for narcolepsy in the second half of the year [33] - **AXS-fourteen**: Focused on fibromyalgia, with plans for a new 12-week fixed-dose trial following FDA feedback [35][36] Intellectual Property - **Patent Portfolio**: Broad coverage for pipeline programs, with settlements reached with multiple first filers [38] Conclusion - **Leadership and Future Outlook**: Strong leadership team and board, with a focus on providing updates throughout the year [40]

Group 1: Summit Therapeutics - Summit Therapeutics' shares have increased over 1,000% in the past three years, primarily due to the progress of ivonescimab, an investigational cancer medicine [2] - Ivonescimab has shown positive results in several phase 2 and phase 3 studies in China and is already approved there, contributing to Summit's market cap of $13.6 billion despite no revenue generation [2][6] - The drug has produced Phase 3 results comparable to Keytruda for non-small cell lung cancer, indicating significant market potential [4] - Ivonescimab is being tested for multiple cancer types, suggesting a robust pipeline for Summit Therapeutics [5] - The company anticipates U.S. approval for ivonescimab within three years, with potential for further approvals in the next decade [6] Group 2: Axsome Therapeutics - Axsome Therapeutics has seen stock market gains of nearly 350% over the past three years due to significant clinical and regulatory milestones [7] - The company’s revenue increased by 62% year over year to $121.5 million in the first quarter, driven by the approval of Auvelity for major depressive disorder and the acquisition of Sunosi for narcolepsy [8] - Axsome is expected to transform its product lineup with new approvals and label expansions in the next three years, including positive trial results for several candidates [9] - The company is conducting multiple clinical studies that could lead to further positive data and regulatory submissions, indicating a strong late-stage pipeline [10]

Axsome Therapeutics (AXSM) FY Conference June 03, 2025 11:40 AM ET Speaker0 To the the William Blair forty fifth Annual Growth Stock Conference. My name is Miles Minto. I'm a senior biotech analyst here at the firm. I cover the neurosciences and genetic medicines, and Axsome has been a day one coverage company for me. So early two thousand seventeen before before the Ascend data actually was when picked up coverage there. You know, obviously a bona fide growth story with a Vality well underway, launch of a ...

| 机器之心报道 | | --- | 编辑：杨文 太疯狂了！AI生成的嘻哈歌手唱Rap以假乱真，网友直呼「看不出破绽」。 来来来，眼尖的朋友请告诉我，下面这个嘻哈歌手唱 rap 的视频到底是真实的，还是 AI 生成的？ 我可以 100% 肯定地说，此为 AI 的手笔。你猜对了吗？ 三天前，X 博主 @blizaine 使用 Google Flow Veo3 和 Suno 4.5 制作了这一视频。画面和开场声音是 Veo3 生成的，歌曲和歌词则用 了 Suno 4.5。 由于效果过于逼真，网友直呼「太疯狂」，甚至还让摇滚老炮回想起了当年的舞台时光。 看样子，Veo 3 刚揭开流量明星的遮羞布，这下子又要让歌手瑟瑟发抖了。 循着这个方向在 X 上逛了一圈，发现不少网友热衷于用 Veo 3 生成演唱会视频，而且一个比一个自然。 比如这个另类摇滚迷幻乐队在一家小酒吧的演出片段。主唱站在麦克风前，边弹吉他边演唱成名曲中的副歌部分，情绪饱满但不激烈；贝斯手、吉他手和鼓手沉 醉其中，身体随节奏摇摆着，几乎找不出什么 bug。 Prompt: Mid 90s footage of an alternative rock sh ...

2025年文化强国建设高峰论坛"文化和科技融合发展"论坛在深圳举行。深圳报业集团记者 葛墨含 摄 科技+文化正在裂变更多可能，AI技术+文化还将碰撞出新火花。5月27日，2025年文化强国建设高峰论 坛"文化和科技融合发展"论坛在深圳举行，与会嘉宾围绕"AI技术赋能文化发展与创新"的主题分享观 点。论坛由中宣部主办，广东省委宣传部、深圳市委宣传部、紫荆文化集团、鹏城实验室承办。 中宣部副部长王纲出席论坛并作主旨演讲。王纲指出，一个国家的综合国力归根到底就是科技硬实力和 文化软实力的集成。回望历史，文明的每一次跨越，都是文化和科技的双向奔赴。王纲强调，审视当 下，时代的重大变革，更加倚重文化力量与科技力量的叠加放大。面向未来，建设文化强国，必须坚定 走好科技赋能文化创新之路。 当天的主题演讲环节，来自高校、科研机构、企业的专家代表围绕AIGC赋能艺术创作、语言智能赋能 文化传播、数字技术赋能文化遗产活态传承、大模型时代文化内容生产变革、科技重塑文化对话、人机 交互技术在文博领域的探索等话题发表了主题发言。 "AIGC到底能不能替代人类进行艺术创作？"中国工程院院士、深圳大学电子与信息工程学院院长丁文 华回应称， ...